Latest News and Events
Filter by
Selections
November 21, 2022
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Read MoreNovember 9, 2022
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
Read MoreNovember 7, 2022
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
Read MoreOctober 13, 2022
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreOctober 11, 2022
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
Read MoreSeptember 1, 2022